Single dose pharmacokinetics of linezolid in infants and children
- 1 December 2000
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in The Pediatric Infectious Disease Journal
- Vol. 19 (12), 1178-1184
- https://doi.org/10.1097/00006454-200012000-00012
Abstract
Linezolid is an oxazolidinone antibiotic with excellent in vitro activity against a number of Gram-positive organisms including antibiotic-resistant isolates. The safety and pharmacokinetics of intravenously administered linezolid were evaluated in children and adolescents to examine the potential for developmental dependence on its disposition characteristics. Fifty-eight children (3 months to 16 years old) participated in this study; 44 received a single 1.5-mg/kg dose and 14 received a single 10-mg/kg dose of linezolid administered by intravenous infusion. Repeated blood samples (n = 10 in children > or = 12 months; n = 8 in children 3 to 12 months) were obtained during 24 h after drug administration, and linezolid was quantitated from plasma by high performance liquid chromatography with mass spectrometry detection. Plasma concentration vs. time data were evaluated with a model independent approach. Linezolid was well-tolerated by all subjects. The disposition of linezolid appears to be age-dependent. A significant although weak correlation between age and total body clearance was observed. The mean (+/- SD) values for elimination half-life, total clearance and apparent volume of distribution were 3.0 +/- 1.1 h, 0.34 +/- 0.15 liter/h/kg and 0.73 +/- 0.18 liter/kg, respectively. Estimates of total body clearance and volume of distribution were significantly greater in children than historical values of adult data. As such maximum achievable linezolid plasma concentrations were slightly lower in children, and concentrations 12 h after a single 10-mg/kg dose were below the MIC90 for selected pathogens with in vitro susceptibility to the drug. Based on these data a linezolid dose of 10 mg/kg given two to three times daily would appear appropriate for use in pediatric therapeutic clinical trials of this agent.Keywords
This publication has 15 references indexed in Scilit:
- In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant staphylococcus aureus and penicillin-resistant streptococcus pneumoniaeDiagnostic Microbiology and Infectious Disease, 1999
- Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococciJournal of Antimicrobial Chemotherapy, 1999
- Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compoundsDiagnostic Microbiology and Infectious Disease, 1999
- Comparative Activities of Clinafloxacin, Grepafloxacin, Levofloxacin, Moxifloxacin, Ofloxacin, Sparfloxacin, and Trovafloxacin and Nonquinolones Linozelid, Quinupristin-Dalfopristin, Gentamicin, and Vancomycin against Clinical Isolates of Ciprofloxacin-Resistant and -Susceptible Staphylococcus aureus StrainsAntimicrobial Agents and Chemotherapy, 1999
- A Novel Antimicrobial Agent Joins the Battle against Resistant BacteriaAnnals of Internal Medicine, 1999
- In-vitro activity of 29 antimicrobial agents against penicillin-resistant and -intermediate isolates of Streptococcus pneumoniae.Journal of Antimicrobial Chemotherapy, 1999
- The Oxazolidinone Linezolid Inhibits Initiation of Protein Synthesis in BacteriaAntimicrobial Agents and Chemotherapy, 1998
- The in-vitro activity of linezolid (U-100766) and tentative breakpointsJournal of Antimicrobial Chemotherapy, 1998
- PHARMACOGENETICS IN PEDIATRICS: Implications for PracticePediatric Clinics of North America, 1997
- Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial InfectionsJournal of Medicinal Chemistry, 1996